Equity Profile
Pre-Earnings Brief
Incyte Corp (INCY) is a biotechnology company focused on discovering, developing, and commercializing innovative medicines, primarily for cancer treatment. With a market cap of $19 billion, it plays a significant role in the healthcare sector, particularly in oncology, which is a major area of investment and research.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
63%
Avg EPS Surprise
-45.09%
Avg Stock Reaction
+0.51%
In the last quarter, Incyte reported an EPS of $1.80, exceeding expectations by nearly 10%. However, the stock price fell by over 8% the following day, indicating market skepticism despite the earnings beat.
Management Promises & Guidance
Analysts are generally optimistic about Incyte's upcoming earnings, expecting it to meet or slightly exceed EPS and revenue estimates. The stock's recent performance suggests investors are cautiously hopeful.
Bull Case
If Incyte beats EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a positive market reaction.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the recent history of mixed reactions to earnings reports.
EPS
$1.37Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$1.2BRevenue figures provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will Incyte's EPS exceed the consensus estimate of $1.37?
A strong EPS performance could indicate effective cost management and strong product demand, which are crucial for investor confidence.
Q2
What guidance will management provide regarding future revenue growth?
Future revenue guidance will be critical in assessing Incyte's growth trajectory and market positioning, especially in a competitive biotech landscape.
Edge
Why consensus could be wrong
The Street may be underestimating Incyte's potential for strong revenue growth based on recent product launches and market demand.
Supporting Evidence
The company's recent EPS surprises indicate a trend of outperforming expectations.
Options pricing suggests a lower volatility expectation than historical averages, which may not reflect the company's growth potential.
Key Risk
If revenue growth significantly exceeds the $1.2 billion consensus, it could shift market sentiment dramatically.
Edge
Pre-commit to what would confirm each case.
The market is weighing Incyte's ability to maintain profitability against potential challenges in the biotech sector.
Bull Confirmed If
An EPS of $1.50 or higher would confirm strong operational performance and investor confidence.
Bear Confirmed If
An EPS below $1.20 would raise concerns about the company's profitability and market demand.
Pre-Earnings Positioning
Implied Move
±2.7%
Historical Avg
±5.5%
The options market is pricing a relatively modest move in the stock, suggesting that traders are anticipating a stable earnings report without significant surprises.
Options are pricing ±2.7% while INCY has averaged ±5.5% over the last 8 prints — setup is pricing cheap.
30d HV
24.8%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.2% (modestly positive historical bias).
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.8M
18,667 sh
1 insider
Net
$1.8M
Net selling
Most Active Insiders· 1 open-market trade
$1.8M
Net selling
Recent Transactions
Apr 17, 2026 · @ $96.50
18,667 sh
$1.8M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Incyte beats expectations, history suggests the stock could rise by around 0.94% on the first trading day post-earnings, confirming a positive outlook.
In-Line / Cautious
If results are in line but management's commentary is cautious, the stock may experience little movement as investors digest the news.
Miss
A miss could lead to a decline in stock price, with history suggesting an average drop of 0.20% in such scenarios.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DOMINOS PIZZA INC